Aptahem AB (publ) (NGM:APTA)

Sweden flag Sweden · Delayed Price · Currency is SEK
1.000
-0.025 (-2.44%)
At close: Dec 4, 2025
-14.53%
Market Cap 20.59M
Revenue (ttm) 2.80M
Net Income (ttm) -6.81M
Shares Out 20.97M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 8,456
Average Volume 21,510
Open 1.000
Previous Close 1.025
Day's Range 0.864 - 1.000
52-Week Range 0.560 - 2.400
Beta 0.46
RSI 42.65
Earnings Date Nov 28, 2025

About Aptahem AB

Aptahem AB (publ), a biotechnology company, develops and sells aptamer-based pharmaceuticals for the treatment of acute life-threatening conditions. The company’s lead products candidate is Apta-1, which is in preclinical stage to prevent the onset of life-threatening organ and tissue damage in sepsis patients. It has collaborations with various academic groups, including Consortium with Orebro University, Seattle Children’s Research Institute, and University Health Network. Aptahem AB (publ) was incorporated in 2014 and is based in Malmö, Swed... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 4
Stock Exchange Nordic Growth Market
Ticker Symbol APTA
Full Company Profile

Financial Performance

In 2024, Aptahem AB's revenue was 3.77 million, a decrease of -63.95% compared to the previous year's 10.46 million. Losses were -8.57 million, -22.90% less than in 2023.

Financial Statements

News

There is no news available yet.